Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Resolve Therapeutics LLC

This article was originally published in Start Up

Executive Summary

A growing number of competing companies are taking fresh approaches to treating lupus. Genentech and MedImmune, for instance, are each working on antibodies intended to directly bind the cytokine known as interferon-alpha, and inhibit its inflammatory effects. Start-up Resolve Therapeutics LLC is developing a compound intended to act in the same pathway as Genentech's and MedImmune's antibodies, but upstream of alpha-interferon. The idea is not to block production of interferon itself, but rather to block events that company founders believe trigger alpha-interferon production in lupus patients.
Advertisement

Related Content

Azano Pharmaceuticals Inc.
SuppreMol GMBH
Benlysta May Lead Wave Of New Approvals For Lupus Drugs
Start-Up Previews (01/2011)
Start-Up Previews (01/2011)
Benlysta May Lead Wave Of New Approvals For Lupus Drugs

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC092061

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel